Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
Recruiting · NCT07041450 · Registry updated 2025-07-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2025-07-01 | NCT07041450 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| C2N Diagnostics | 1 |
| MoCA Clinic and Institute | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MoCA Clinic and Institute | Greenfield Park | Canada | 1 |